Chemical synthesis of grafted cyclotides using a "plug and play" approach.


Journal

RSC chemical biology
ISSN: 2633-0679
Titre abrégé: RSC Chem Biol
Pays: England
ID NLM: 101768727

Informations de publication

Date de publication:
05 Jun 2024
Historique:
received: 09 01 2024
accepted: 23 04 2024
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 7 6 2024
Statut: epublish

Résumé

Cyclotides are a diverse class of plant-derived cyclic, disulfide-rich peptides with a unique cyclic cystine knot topology. Their remarkable structural stability and resistance to proteolytic degradation can lead to improved pharmacokinetics and oral activity as well as selectivity and high enzymatic stability. Thus, cyclotides have emerged as powerful scaffold molecules for designing peptide-based therapeutics. The chemical engineering of cyclotides has generated novel peptide ligands of G protein-coupled receptors (GPCRs), today's most exploited drug targets. However key challenges potentially limit the widespread use of cyclotides in molecular grafting applications. Folding of cyclotides containing bioactive epitopes remains a major bottleneck in cyclotide synthesis. Here we present a modular 'plug and play' approach that effectively bypasses problems associated with the oxidative folding of cyclotides. By grafting onto a pre-formed acyclic cyclotide-like scaffold we show that difficult-to-graft sequences can be easily obtained and can target GPCRs with nanomolar affinities and potencies. We further show the suitability of this new method to graft other complex epitopes including structures with additional disulfide bonds that are not readily available

Identifiants

pubmed: 38846076
doi: 10.1039/d4cb00008k
pii: d4cb00008k
pmc: PMC11151825
doi:

Types de publication

Journal Article

Langues

eng

Pagination

567-571

Informations de copyright

This journal is © The Royal Society of Chemistry.

Déclaration de conflit d'intérêts

There are no conflicts to declare.

Auteurs

Johannes Koehbach (J)

Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland Brisbane Queensland Australia koehbachjohannes@gmail.com d.craik@imb.uq.edu.au.
School of Biomedical Sciences, The University of Queensland Brisbane Queensland Australia.

Edin Muratspahić (E)

Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna Vienna Austria.

Zakaria M Ahmed (ZM)

School of Biomedical Sciences, The University of Queensland Brisbane Queensland Australia.

Andrew M White (AM)

Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland Brisbane Queensland Australia koehbachjohannes@gmail.com d.craik@imb.uq.edu.au.
Research School of Chemistry, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, Australian National University Australia.

Nataša Tomašević (N)

Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna Vienna Austria.

Thomas Durek (T)

Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland Brisbane Queensland Australia koehbachjohannes@gmail.com d.craik@imb.uq.edu.au.

Richard J Clark (RJ)

School of Biomedical Sciences, The University of Queensland Brisbane Queensland Australia.

Christian W Gruber (CW)

Center for Physiology and Pharmacology, Institute of Pharmacology, Medical University of Vienna Vienna Austria.

David J Craik (DJ)

Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland Brisbane Queensland Australia koehbachjohannes@gmail.com d.craik@imb.uq.edu.au.

Classifications MeSH